Lilly's EBGLYSS Monotherapy Met Primary And Secondary Endpoints At Week 16 In Its Phase 3B ADtouch Study, Showing Significant And Rapid Improvements In Hand And Foot Skin Clearance, Itch And Pain In Adults And Adolescents With Moderate-To-Severe Hand And Foot Atopic Dermatitis
In first-of-its-kind patient satisfaction data for moderate-to-severe hand AD, significantly more patients treated with EBGLYSS were satisfied or very satisfied with how much the skin on their hands had cleared than
Lilly's new skin medicine worked really well in testing. When a company proves its medicine truly helps people, that's a sign of real progress.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.